《大行報告》野村下調藥明康德(02359.HK)目標價至98.96元 評級「買入」
野村發表研究報告指出,維持對藥明康德(02359.HK)今明兩年的收入預測,較市場預期的低1%及7%;另對公司盈利預測下調3.7%及1.1%,以反映經營利潤率較高及非經常性其他收入(如金融和生物資產的公允值變化)較低的影響,亦較市場預期低11%及19%。
該行將藥明康德的目標價由113.83元下調至98.96元,主要由於港元兌人民幣走強,且擴大A/H股溢價預測(由15%擴至20%),維持「買入」評級,並看好其在中國合同研究組織(CRO)領域的領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.